Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Analysis of dermatologic events in patients with cancer treated with lapatinib.

Lacouture ME, Laabs SM, Koehler M, Sweetman RW, Preston AJ, Di Leo A, Gomez HL, Salazar VM, Byrne JA, Koch KM, Blackwell KL.

Breast Cancer Res Treat. 2009 Apr;114(3):485-93. doi: 10.1007/s10549-008-0020-7. Epub 2008 Jul 4. Review.

PMID:
18600445
2.

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib.

Crown JP, Burris HA 3rd, Boyle F, Jones S, Koehler M, Newstat BO, Parikh R, Oliva C, Preston A, Byrne J, Chan S.

Breast Cancer Res Treat. 2008 Nov;112(2):317-25. doi: 10.1007/s10549-007-9860-9. Epub 2008 Jan 20. Erratum in: Breast Cancer Res Treat. 2009 Jan;113(2):409-10.

PMID:
18204897
3.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D.

N Engl J Med. 2006 Dec 28;355(26):2733-43. Erratum in: N Engl J Med. 2007 Apr 5;356(14):1487.

4.

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.

Medina PJ, Goodin S.

Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. Review.

PMID:
18803986
5.

FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko CW, Sridhara R, Justice R, Pazdur R.

Oncologist. 2008 Oct;13(10):1114-9. doi: 10.1634/theoncologist.2008-0816. Epub 2008 Oct 10.

6.

A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.

Park IH, Lee KS, Kang HS, Kim SW, Lee S, Jung SY, Kwon Y, Shin KH, Ko K, Nam BH, Ro J.

Invest New Drugs. 2012 Oct;30(5):1972-7. doi: 10.1007/s10637-011-9759-5. Epub 2011 Oct 18.

PMID:
22006161
7.

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.

Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE.

Breast Cancer Res Treat. 2008 Dec;112(3):533-43. doi: 10.1007/s10549-007-9885-0. Epub 2008 Jan 11.

PMID:
18188694
8.

Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.

Gajria D, Gonzalez J, Feigin K, Patil S, Chen C, Theodoulou M, Drullinsky P, D'Andrea G, Lake D, Norton L, Hudis CA, Traina TA.

Breast Cancer Res Treat. 2012 Jan;131(1):111-6. doi: 10.1007/s10549-011-1749-y. Epub 2011 Sep 4.

PMID:
21898114
9.

Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.

Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE.

Oncologist. 2010;15(9):924-34. doi: 10.1634/theoncologist.2009-0181. Epub 2010 Aug 24.

10.

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.

Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL.

J Clin Oncol. 2005 Aug 10;23(23):5305-13. Epub 2005 Jun 13.

PMID:
15955900
11.

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M.

J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28.

PMID:
19786658
12.

Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.

Cameron DA, Stein S.

Nat Clin Pract Oncol. 2008 Sep;5(9):512-20. doi: 10.1038/ncponc1156. Epub 2008 Jul 1. Review.

PMID:
18594499
13.

Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience.

Crivellari D, Spazzapan S, Lombardi D, Militello L, Torrisi E, Russo AE, Sorio R, Talamini R, Miolo G, Carli P, Veronesi A.

Tumori. 2012 Jan-Feb;98(1):33-8. doi: 10.1700/1053.11497.

PMID:
22495699
14.

Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.

Finn RS, Gagnon R, Di Leo A, Press MF, Arbushites M, Koehler M.

J Clin Oncol. 2009 Nov 20;27(33):5552-8. doi: 10.1200/JCO.2008.21.1763. Epub 2009 Oct 26.

PMID:
19858400
15.

Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.

Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V, Spector N.

J Clin Oncol. 2010 Jul 10;28(20):3248-55. doi: 10.1200/JCO.2009.21.8594. Epub 2010 Jun 7.

PMID:
20530274
16.

Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.

Simonelli M, Zucali PA, Lorenzi E, Rubino L, De Vincenzo F, De Sanctis R, Perrino M, Mancini L, Di Tommaso L, Rimassa L, Masci G, Zuradelli M, Suter MB, Bertossi M, Fattuzzo G, Giordano L, Roncalli MG, Santoro A.

Eur J Cancer. 2013 Mar;49(5):989-98. doi: 10.1016/j.ejca.2012.10.016. Epub 2012 Nov 9.

PMID:
23146956
17.

[Lapatinib treatment-option in trastuzumab-resistant breast cancer].

Pikó B.

Magy Onkol. 2009 Dec;53(4):369-75. doi: 10.1556/MOnkol.53.2009.4.6. Review. Hungarian.

18.

High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.

Rhee J, Han SW, Cha Y, Ham HS, Kim HP, Oh DY, Im SA, Park JW, Ro J, Lee KS, Park IH, Im YH, Bang YJ, Kim TY.

Breast Cancer Res Treat. 2011 Jan;125(1):107-14. doi: 10.1007/s10549-010-1200-9. Epub 2010 Oct 9.

PMID:
20936340
19.

High lapatinib plasma levels in breast cancer patients: risk or benefit?

Cizkova M, Bouchalova K, Friedecky D, Polynkova A, Janostakova A, Radova L, Cwiertka K, Trojanec R, Zezulova M, Zlevorova M, Hajduch M, Melichar B.

Tumori. 2012 Jan-Feb;98(1):162-5. doi: 10.1700/1053.11516.

20.

Lapatinib for the treatment of HER2-overexpressing breast cancer.

Jones J, Takeda A, Picot J, von Keyserlingk C, Clegg A.

Health Technol Assess. 2009 Oct;13 Suppl 3:1-6. doi: 10.3310/hta13suppl3/01. Review.

Supplemental Content

Support Center